Sainz’s appointment becomes effective Oct. 24, 2022. Scott Huennekens, the current interim president and CEO, remains on as executive chairperson of the board.
Guilford, Connecticut–based Hyperfine develops the Swoop FDA-cleared portable MRI system.
“I am excited and honored to lead the next phase of Hyperfine’s growth as we broaden the adoption of Swoop technology, improving access to MR imaging around the world,” said Sainz. “With over 90 systems installed globally and our growing value proposition in the ICU and neurocritical care settings, we have established a strong foundation to drive forward commercial momentum. I am eager to join the Hyperfine team as we expand to additional hospitals and continue increasing our clinical applications to improve patient care in mature and emerging healthcare systems.”
Sainz joins the company having served as president and CEO at multiple medical device companies. That list includes AEGEA Medical (acquired by CooperSurgical in 2021), Cardiokinetix and Concentric Medical (acquired by Stryker in 2011). She brings more than 30 years of experience in the medical device industry.
Sainz is familiar with Hyperfine
Additionally, Sainz has served on Hyperfine’s board of directors since the company’s Nasdaq listing following a SPAC merger in 2021. She served on both the company’s audit committee and nominating and corporate governance committee.
Sainz’s role as president and CEO includes leading the commercial expansion of the Swoop system. The aim is to execute the company’s mission of “lowering barriers to medical imaging around the world.”
“We are very pleased to name Ms. Sainz president and CEO of Hyperfine. She carries a successful track record of execution and shareholder value creation across medical device businesses, and her decades of experience are immensely valuable,” said Huennekens. “I am confident in her ability to manage the business with a disciplined approach to spending while leading Hyperfine into its next phase of growth by expanding the Swoop commercial footprint to new sites of care.”
